ERBB2 amplification

About

Gene context: ERBB2

Biomarker Type: Copy Number

Present: True

Direction: Amplification

Legacy biomarker representation, assumes GRCh37 / hg19 genome build.

Mappings

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	ERBB2 amplification	Invasive Breast Carcinoma	Docetaxel, Trastuzumab
Sensitivity (+)	ERBB2 amplification	Invasive Breast Carcinoma	Trastuzumab deruxtecan
Sensitivity (+)	ERBB2 amplification	Non-Small Cell Lung Cancer	Trastuzumab deruxtecan
Sensitivity (+)	ERBB2 amplification	Adenocarcinoma of the Gastroesophageal Junction	Trastuzumab deruxtecan
Sensitivity (+)	ERBB2 amplification	Invasive Breast Carcinoma	Trastuzumab
Sensitivity (+)	ERBB2 amplification	Invasive Breast Carcinoma	Paclitaxel, Trastuzumab
Sensitivity (+)	ERBB2 amplification	Invasive Breast Carcinoma	Docetaxel, Trastuzumab
Sensitivity (+)	ERBB2 amplification	Invasive Breast Carcinoma	Anastrozole, Trastuzumab
Sensitivity (+)	ERBB2 amplification	Invasive Breast Carcinoma	Trastuzumab
Sensitivity (+)	ERBB2 amplification	Invasive Breast Carcinoma	Paclitaxel, Trastuzumab
Sensitivity (+)	ERBB2 amplification	Invasive Breast Carcinoma	Docetaxel, Trastuzumab
Sensitivity (+)	ERBB2 amplification	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Trastuzumab
Sensitivity (+)	ERBB2 amplification	Invasive Breast Carcinoma	Doxorubicin, Paclitaxel, Trastuzumab
Sensitivity (+)	ERBB2 amplification	Esophagogastric Adenocarcinoma	Capecitabine, Cisplatin, Trastuzumab
Sensitivity (+)	ERBB2 amplification	Esophagogastric Adenocarcinoma	Cisplatin, Fluorouracil, Trastuzumab
Sensitivity (+)	ERBB2 amplification	Invasive Breast Carcinoma	Trastuzumab emtansine
Sensitivity (+)	ERBB2 amplification	Invasive Breast Carcinoma	Trastuzumab emtansine
Sensitivity (+)	ER positive, ERBB2 amplification, PR positive	Invasive Breast Carcinoma	Neratinib
Sensitivity (+)	ER positive, ERBB2 amplification	Invasive Breast Carcinoma	Neratinib
Sensitivity (+)	ERBB2 amplification, PR positive	Invasive Breast Carcinoma	Neratinib
Sensitivity (+)	ERBB2 amplification	Invasive Breast Carcinoma	Capecitabine, Lapatinib
Sensitivity (+)	ER positive, ERBB2 amplification, PR negative	Invasive Breast Carcinoma	Lapatinib, Trastuzumab
Sensitivity (+)	ER positive, ERBB2 amplification, PR positive	Invasive Breast Carcinoma	Lapatinib, Letrozole
Sensitivity (+)	ER positive, ERBB2 amplification, PR positive	Invasive Breast Carcinoma	Neratinib
Sensitivity (+)	ER positive, ERBB2 amplification	Invasive Breast Carcinoma	Neratinib
Sensitivity (+)	ERBB2 amplification, PR positive	Invasive Breast Carcinoma	Neratinib